We are delighted to report that the first patient has now enrolled in the MISTIE III intracerebral hemorrhage trial! In the race to be the first out-of-the-gate, the honor goes to Hartford Hospital.
Dr. Inam Kureshi and his team at Hartford enrolled patient #1 at 17:02 on 30-Dec-2013, marking the official start of the study period. Congratulations go out to the Hartford team which includes the coordinator, Sara Jasak, RN, and the neurointensivist, Dr. Robert Brown. This was the 12th patient to be screened at this site since the site was activated on 11-December. We are especially proud of how Sara Jasak has entered the clinical data in near real-time; just a few days into the acute treatment and we already have 54 final case form pages with no open queries! Way to go, Sara!
It was a close race. Within 3 days, the second patient was enrolled on 02-Jan-2014, this time at Barrow Neurological Institute in Phoenix by Dr. Peter Nakaji, with indespensible help from Dr. Norissa Hornea serving as study coordinator and from Dr. Shawn Wright in the neurointensivist role. This was the 7th patient to be screened at this site since the site was activated on 20-December.
Our third site to be activated, Gwinnett Medical Center in Lawrenceville Virginia, already has 4 screens under their belt since activating on 23-December so we are eagerly awaiting a randomization from Dr. Michael Stechison and his team. Most high-performing sites, like these 3 that worked so hard to get their sites ready for the trial as quickly as possible, randomize one patient for every 10 screens or so.
Another 5 sites (Abington Memorial Hospital in Pennsylvania, Johns Hopkins in Baltimore, Maine Medical Center in Portland, Miami Valley Hospital in Dayton and St. Lukes Hospital in Kansas City) have been activated in the last few days and should start screening patients shortly.
Fifty sites attended the 08-09 November launch meeting. Most of them will be activated by the end of January as they complete the final few startup hurdles. Plans are now underway to launch the European and Asian sites this summer.
We are well on the path to meeting our goal of 50 patients this year and 500 by 2017. Our appreciation and congratulations go out to all the clinical sites who have worked so hard to successfully launch this important clinical trial.